Sonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73 weeks

JAAD Int. 2022 Oct 18:10:31-33. doi: 10.1016/j.jdin.2022.08.027. eCollection 2023 Mar.

Michael Migden^{1

2}, Carmen Loquai³, Caroline Robert⁴, Jean-François Baurain^{5

6}, Nicholas Squittieri⁷, Ramon Arntz⁸, Jörg Dierlamm⁸, Brigitte Dréno⁹

¹ Department of Dermatology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.
² Department of Head and Neck Surgery, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.
³ Department of Dermatology, University Medical Center Mainz, Mainz, Germany.
⁴ Department of Dermatology, Institut Gustave Roussy and Paris-Saclay University, Villejuif, France.
⁵ Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, UCLouvain, Brussels, Belgium.
⁶ Institute for Experimental and Clinical Research, Université catholique de Louvain, Brussels, Belgium.
⁷ Medical Affairs Oncology, Sun Pharmaceutical Industries, Inc, Princeton, New Jersey.
⁸ Sun Pharmaceutical Industries, (Europe) B.V., Hoofddorp, North Holland, the Netherlands.
⁹ Department of Dermatology, University Hospital Nantes, Nantes, France.

No abstract available